Compare MWA & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MWA | ACAD |
|---|---|---|
| Founded | 1857 | 1993 |
| Country | United States | United States |
| Employees | 3500 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.9B |
| IPO Year | 2006 | 2000 |
| Metric | MWA | ACAD |
|---|---|---|
| Price | $30.26 | $21.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 22 |
| Target Price | $30.50 | ★ $30.55 |
| AVG Volume (30 Days) | 788.5K | ★ 1.7M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | 64.86 | ★ 69.12 |
| EPS | 0.27 | ★ 2.30 |
| Revenue | ★ $1,429,700,000.00 | $726,437,000.00 |
| Revenue This Year | $4.85 | $18.90 |
| Revenue Next Year | $4.20 | $11.62 |
| P/E Ratio | $112.69 | ★ $9.33 |
| Revenue Growth | 8.75 | ★ 40.45 |
| 52 Week Low | $22.74 | $14.08 |
| 52 Week High | $31.00 | $28.35 |
| Indicator | MWA | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 66.28 | 48.71 |
| Support Level | $26.66 | $20.22 |
| Resistance Level | $30.74 | $22.03 |
| Average True Range (ATR) | 0.76 | 0.73 |
| MACD | 0.34 | 0.11 |
| Stochastic Oscillator | 89.20 | 55.86 |
Mueller Water Products Inc is a U.S.-based company that manufactures and sells products and services used in the transmission, distribution, and measurement of water. The company operates in two segments: Water Flow Solutions and Water Management Solutions. The Water Flow Solutions segment, which derives maximum revenue for the company, includes products like iron gate valves, specialty valves, and service brass products. Water Management Solutions' portfolio includes fire hydrants, repair and installation, natural gas, metering, leak detection, and pressure management and control products and solutions. Geographically, the company derives a majority of its revenue from the United States and the rest from Canada and other international locations.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.